Search

Dealing with EGFRex19del & L858R, ALK, and K-RasG12C...

Edgardo Santos, MD

Uncommon Mutations/ Fusions: EGFRex20, RET, MET, HER2, NRG1

Stephen Liu, MD

Neo-Adjuvant and Adjuvant Immunotherapy for Non-Small Cell Lung...

Luis Raez, MD

How to Choose Front- Line Therapy for Metastatic...

How to Choose Front- Line Therapy for Metastatic NSCLC Without Driver Mutations

Stage III NSCLC: Beyond the PACIFIC/ Novel Approaches

Jorge Gomez, MD

Plasma Genotyping in NSCLC: Layering in the Liquid...

Benjamin Levy, MD

Toxicity Management of Novel Agents in Lung Cancer

Khurrum Qureshi, PharmD

Roundtable Discussion

Howard (Jack) West, MD & Sandip Patel, MD

Lung Adenocarcinoma Updates

Howard (Jack) West, MD

Squamous NSCLC and Small Cell Lung Cancer Update

Sandip Patel, MD

New Developments for Locally Advances Lung Cancer

Diana Saravia, MD

New Therapies for Squamous Cell and Small Cell...

Alberto Chiappori, MD

Addressing RET, MET, and EGFR/HER-2 Exon 20 insertion

Pedro Solivan, MD

Non-Small Cell Lung Cancer: EGFR, ALK, & K-Ras...

Edgardo Santos, MD, FACP

Neo-Adjuvant and Adjuvant Immuntherapy for Non-Small Cell Lung...

Luis Raez, MD, FACP, FCCP

RET, MET & B-RAF mutations in NSCLC

Janakiraman Subramanian, MD, MPH

ERBB2 and NGR1 Pathways in NSCLC

Estelamari Rodriguez, MD

ALK, ROS1 & NTRK Mutations in NSCLC

Corey Langer, MD

EGFR and K-RAS Mutations in NSCLC

Edgardo S. Santos Castillero, MD

Lung Cancer Clinical Scenarios: How Liquid Biopsy Technology...

Christian Rolfo, MD